| Drug Name: | mianserin (24219-97-4) |
|---|---|
| PubChem ID: | 4184 |
| SMILES: | CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42 |
| InchiKey: | UEQUQVLFIPOEMF-UHFFFAOYSA-N |
| Therapeutic Category: | Adrenergic Agents, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Antidepressive Agents, Central Nervous System Agents, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Neurotransmitter Agents, Psychotropic Drugs, Serotonin Agents, Serotonin Antagonists |
| Molecular Weight (dalton) | : | 264.372 |
| LogP | : | 3.0839 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 2 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 6.48 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Toxicity And Inefficacy | CYP2D6 (P10635) | Toxicity in poor metabolisers@ inefficacy in ultrarapid metabolisers. [ ADR Type 3 ] | Drugs in special patient groups: clinical importance of genomics in drug effects In: Carruthers GS, Hoffmann BB,Melmon KL, Nierenberg DW |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category